Educational, research-use-only content. This article summarizes published scientific literature for informational purposes only and is not medical advice. The compounds discussed are supplied strictly for in-vitro laboratory research and are not approved for human or veterinary use.
What is tesamorelin?
Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone (GHRH). Rather than supplying growth hormone directly, it stimulates the pituitary to synthesize and release the body’s own growth hormone in a more natural, pulsatile pattern (Dhillon, 2011).
What the clinical research examined
Tesamorelin is unusual among research peptides in that it has been studied in large, well-designed human trials. In two 26-week randomized controlled trials in patients with HIV-associated central fat accumulation, subcutaneous tesamorelin significantly reduced visceral adipose tissue (the deep abdominal fat around organs) without meaningfully reducing subcutaneous fat. The reduction was maintained through 52 weeks in extension phases — but visceral fat re-accumulated after the drug was stopped, indicating the effect depended on continued use (Dhillon, 2011).
How it is thought to work
By raising endogenous growth hormone and downstream IGF-1, tesamorelin shifts fat handling toward lipolysis in visceral depots. Because it works through the body’s own regulatory axis, its growth-hormone exposure is generally more physiologic than injecting recombinant growth hormone directly (Dhillon, 2011).
Tolerability and regulatory status
In the trials, serious treatment-emergent events were uncommon; the most frequent issues were injection-site reactions and effects typical of growth-hormone therapy such as joint pain, headache, and fluid retention. Importantly, tesamorelin is approved by the U.S. Food and Drug Administration only for reducing excess abdominal fat in HIV-associated lipodystrophy — not for general weight loss, body-building, or “anti-aging.” The material sold here is for laboratory research use only.
The limits of the current evidence
- Human efficacy data are specific to the HIV-lipodystrophy population; they do not establish benefit or safety for other uses.
- Effects reverse on discontinuation, and growth-hormone-axis stimulation carries known risks that require medical oversight.
References
According to PubMed:
- Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011. doi:10.2165/11202240-000000000-00000
- Dhillon S. Spotlight on tesamorelin in HIV-associated lipodystrophy. BioDrugs. 2011. doi:10.2165/11208290-000000000-00000
